Cleared Traditional

K234065 - CDI OneView Monitoring System

K234065 is an FDA 510(k) clearance for CDI OneView Monitoring System, manufactured by Terumo Cardiovascular Systems Corporation. The device is a Class 2 Cardiovascular device with product code DRY cleared through the Traditional 510(k) pathway after a 125-day FDA review.

K234065 · Terumo Cardiovascular Systems Corporation · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2024
Decision
125d
Days
Class 2
Risk

K234065 is an FDA 510(k) clearance for the CDI OneView Monitoring System. Classified as Monitor, Blood-gas, On-line, Cardiopulmonary Bypass (product code DRY), Class II - Special Controls.

Submitted by Terumo Cardiovascular Systems Corporation (Ann Arbor, US). The FDA issued a Cleared decision on April 25, 2024 after a review of 125 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.4330 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Terumo Cardiovascular Systems Corporation devices

FDA 510(k) Submission Details - K234065

510(k) Number K234065 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 22, 2023
Decision Date April 25, 2024
Days to Decision 125 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
At panel average
Panel avg: 125d · This submission: 125d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DRY Device Classification - Class 2, Special Controls

Product Code DRY Monitor, Blood-gas, On-line, Cardiopulmonary Bypass
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.4330
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DRY Monitor, Blood-gas, On-line, Cardiopulmonary Bypass

All 21
Devices cleared under the same product code (DRY) and FDA review panel - the closest regulatory comparables to K234065.
B-Capta
K202154 · Livanova Deutschland, GmbH · Apr 2021
Quantum Workstation 12 Elite
K202557 · Spectrum Medical , Ltd. · Oct 2020
CDI Blood Parameter Monitoring System 550
K182110 · Terumo Cardiovascular Systems Corporation · Nov 2018
Quantum Workstation 12.1
K181923 · Spectrum Medical , Ltd. · Aug 2018
Quantum Diagnostic Module, Quantum Diagnostic Module - No Gas
K173591 · Spectrum Medical , Ltd. · Mar 2018
TRI-OPTIC MEASUREMENT CELL
K133157 · Medtronic, Inc. · Oct 2014